Medical Oncologist Calls for More Research and Improved Access to Reduce Incidence of de Novo Metastatic Breast Cancer
Wake Forest University School of MedicineDespite the widespread use of mammography screening, the incidence of de novo metastatic breast cancer has not declined and represents 3% to 6% of new breast cancer diagnoses in high-income countries and 10% to 30% in low-income countries. De novo metastatic breast cancer refers to breast cancer that has already spread to distant sites (liver, brain, lung or bone) at a patient’s initial diagnosis and has a five-year survival rate of around 29%.